How do you approach Lu-177 use in taxane-naive patients with metastatic prostate cancer?

With the recent publication of PSMAfore, what are your current criteria for offering Lu-177 therapy?

Answer from: Medical Oncologist at Academic Institution

At this time in October 2024, Lu177-PSMA-617 is not yet approved in taxane-naive mCRPC, and decisions on its use and availability hinge both on USFDA approval in the coming months as well as NCCN guidance, which has not been updated at this time. Until then, decisions to pursue this radioligand ther...

Comments

Radiation Oncologist at Oncology Nevada
This is very helpful. Thank you. So for your pract...

Please select the option that best describes you:

How do you approach Lu-177 use in taxane-naive patients with metastatic prostate cancer?

Related Questions